Medicina, Vol. 47 No. 4, 2011.
Kratko priopćenje
Imatinib mesylat in the treatment of chronic myeloid leukemia relapse after allogeneic stem cell transplantation – case report
Marijo Vodanović
; Zavod za hematologiju, Klinika za unutarnje bolesti, KBC Zagreb, Zagreb, Hrvatska
Ranka Serventi-Seiwerth
; Zavod za hematologiju, Klinika za unutarnje bolesti, KBC Zagreb, Zagreb, Hrvatska
Dubravka Sertić
; Zavod za hematologiju, Klinika za unutarnje bolesti, KBC Zagreb, Zagreb, Hrvatska
Sanja Davidović
; Zavod za laboratorijsku dijagnostiku, KBC Zagreb, Zagreb, Hrvatska
Renato Zadro
; Zavod za laboratorijsku dijagnostiku, KBC Zagreb, Zagreb, Hrvatska
Vinko Bogdanić
; Zavod za hematologiju, Klinika za unutarnje bolesti, KBC Zagreb, Zagreb, Hrvatska
Dražen Pulanić
; Zavod za hematologiju, Klinika za unutarnje bolesti, KBC Zagreb, Zagreb, Hrvatska
Boris Labar
; Zavod za hematologiju, Klinika za unutarnje bolesti, KBC Zagreb, Zagreb, Hrvatska
Sažetak
Aim: We present a case of a patient with a Philadelphia positive chronic myeloid leukemia treated with imatinib because of relapse after allogeneic stem cell transplantation. Case report: Ten years after allogenic stem cell transplantation in a patient with Philadelphia positive chronic myeloid leukemia relapse was documented. Therapy with imatinib in a dose of 400 mg/day was stared. Hematologic and cytogenetic remission with a good molecular response was documented 6 months after therapy. Cytogenetic analysis was performed to evaluate chimerisms, however all cells had a normal female karyotype (the donor was the patient’s sister). These findings confirm the restoration of donor hematopoiesis. Discussion and conclusion: Tyrosine kinase inhibitors are very effective drugs in controlling Philadelphia positive chronic myeloid leukemia. Therapy is also effective in controlling the disease in patients with disease relapse after allogeneic stem cell transplantation.
Ključne riječi
allogeneic stem cell transplantation; imatinib; Philadelphia positive chronic myeloid leukemia
Hrčak ID:
76677
URI
Datum izdavanja:
1.12.2011.
Posjeta: 2.548 *